Highlights of This Issue

SPECIAL FEATURES

CCR Translations

Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
Hariharan Easwaran and Stephen B. Baylin
See article p. 2360

Double Down for a Double Win
Pearl S. Huang
See article p. 2316

Competing Risk Analyses: How Are They Different and Why Should You Care?
Rick Chappell
See article p. 2301

Choosing Phase II Endpoints and Designs: Evaluating the Possibilities
Michael LeBlanc and Catherine Tangen
See article p. 2309

Molecular Pathways

Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications
Robert J. Biggar

Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus
Liying Yang, Fritz Francois, and Zhiheng Pei

Review

Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment
Anjel A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, and Meletios A. Dimopoulos

HUMAN CANCER BIOLOGY

Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL
Nakao Kanemitsu, Yasushi Isobe, Azuchi Masuda, Shuii Momose, Moriohiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu

Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinoma and Squamous Cell Carcinoma

CANCER THERAPY: PRECLINICAL

RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine—Redirected T Cells
Christine E. Brown, Renate Starr, Brenda Aguilar, Andrew F. Shami, Catalina Martinez, Massimo D’Apuzzo, Michael E. Barish, Stephen J. Forman, and Michael C. Jensen

Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Daruka Mahadevan, Amy Stejskal, Laurence S. Cooke, Ann Munziello, Carla Morales, Daniel O. Persky, Richard J. Fisher, Thomas P. Miller, and Wenqing Qi
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2220</td>
<td>First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway</td>
<td>Kanjoormana A. Manu, Muthu K. Shanmugam, Lalitha Ramachandran, Feng Li, Chee Wai Fong, Alan Prem Kumar, Patrick Tan, and Gautam Sethi</td>
</tr>
<tr>
<td>2230</td>
<td>The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin</td>
<td>Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Eline Menu, Els Van Valkenborgh, Elke De Bryune, Anders Osterborg, Peter Atadja, Olle Larsson, Magnus Axelson, Ben Van Camp, Helena Jerneberg-Wiklund, and Karin Vanderkerken</td>
</tr>
<tr>
<td>2240</td>
<td>Improved Efficacy of Dendritic Cell–Based Immunotherapy by Cutaneous Laser Illumination</td>
<td>Xinyuan Chen, Qiyan Zeng, and Mei X. Wu</td>
</tr>
<tr>
<td>2250</td>
<td>Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas</td>
<td>Kan Zhai, Xianbo Tian, Chen Wu, Ning Lu, Jiang Chang, Liming Huang, Tongwen Zhang, Yu Lin Zhou, Yan Qiao, Dianke Yu, Wen Tan, Jieping Chen, and Dongxin Lin</td>
</tr>
<tr>
<td>2257</td>
<td>Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review</td>
<td>Xiaoyun Liao, Teppie Morikawa, Paul Lochhead, Yu Imamura, Aya Kuchiba, Mai Yamauchi, Katsuhiko Nosho, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Charles S. Fuchs, and Shuji Ogino</td>
</tr>
<tr>
<td>2269</td>
<td>cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes</td>
<td>Kanwal P. Bagh, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein Jr, and Ana M. Gonzalez-Angulo</td>
</tr>
<tr>
<td>2290</td>
<td>Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma</td>
<td>Josep M. Llovet, Carol E.A. Peña, Chetan D. Lathia, Michael Shan, Gerold Meinhardt, and Jordi Bruix on behalf of the SHARP Investigators Study Group</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2250</td>
<td>Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas</td>
<td>Kan Zhai, Xianbo Tian, Chen Wu, Ning Lu, Jiang Chang, Liming Huang, Tongwen Zhang, Yu Lin Zhou, Yan Qiao, Dianke Yu, Wen Tan, Jieping Chen, and Dongxin Lin</td>
</tr>
<tr>
<td>2257</td>
<td>Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review</td>
<td>Xiaoyun Liao, Teppie Morikawa, Paul Lochhead, Yu Imamura, Aya Kuchiba, Mai Yamauchi, Katsuhiko Nosho, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Charles S. Fuchs, and Shuji Ogino</td>
</tr>
<tr>
<td>2269</td>
<td>cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes</td>
<td>Kanwal P. Bagh, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein Jr, and Ana M. Gonzalez-Angulo</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2301</td>
<td>The Use and Interpretation of Competing Risks Regression Models</td>
<td>James J. Dignam, Qiang Zhang, and Masha Kocherginsky</td>
</tr>
<tr>
<td>2309</td>
<td>Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints</td>
<td>Manish R. Sharma, Theodore G. Karrison, Yuyan Jin, Robert B. Bies, Michael L. Maitland, Walter M. Stadler, and Mark J. Ratain</td>
</tr>
<tr>
<td>2326</td>
<td>BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency</td>
<td>David S. Hong, Luis Vence, Gerald Falchook, Laszlo G. Radavanyi, Chengwen Liu, Vicki Goodman, Jeffery J. Legos, Sam Blackman, Antonio Scarmadio, Razelle Kurzrock, Gregory Lizée, and Patrick Hwu</td>
</tr>
</tbody>
</table>

**RESOURCES**

- [clincancerres.aacjournals.org](http://clincancerres.aacjournals.org)
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummar, Eva Szabo, Mary Ann Yancey, Jiuping Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, and Giuseppe Giaccone

Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study
Jonathan Shamash, Jimmy Jacob, Samir Agrawal, Thomas Powles, Katherine Mutsangwga, Peter Wilson, and Justin Stebbing

DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
Kim Walter, Thomas Holcomb, Tom Januario, Pan Du, Marie Evangelista, Nithya Kartha, Leonardo Iniguez, Robert Soriano, Ling Huw, Howard Stern, Zora Modrusan, Somasekar Seshagiri, Garret M. Hampton, Lukas C. Amler, Richard Bourgon, Robert L. Yauch, and David S. Shames
See commentary p. 2121

Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth
Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates

Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment
David N. Finegold, Catherine J. Baty, Kelly Z. Knickelbein, Shelley Perschke, Sarah E. Noon, Diana Campbell, Jenny M. Karlsson, Diana Huang, Mark A. Kimak, Elizabeth C. Lawrence, Eleanor Feingold, Stephen D. Meriney, Adam M. Bruisky, and Robert E. Ferrell

Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
Elizabeth A. Punnoose, Siminder Atwal, Weiquan Liu, Rajiv Baja, Bernard M. Fine, Brett G.M. Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkall, and Mark R. Lackner

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

CORRECTION
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.
Clinical Cancer Research

18 (8)


| Updated version | Access the most recent version of this article at: http://clincancerres.aacrjournals.org/content/18/8 |

| E-mail alerts       | Sign up to receive free email-alerts related to this article or journal. |
| Reprints and Subscriptions | To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. |
| Permissions        | To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/18/8. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. |